Insider Selling: Vaxcyte (NASDAQ:PCVX) CFO Sells $538,900.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 10,000 shares of the stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $53.89, for a total transaction of $538,900.00. Following the completion of the sale, the chief financial officer owned 105,176 shares of the company’s stock, valued at approximately $5,667,934.64. The trade was a 8.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Andrew Guggenhime also recently made the following trade(s):

• On Monday, July 6th, Andrew Guggenhime sold 10,000 shares of Vaxcyte stock. The stock was sold at an average price of $57.28, for a total value of $572,800.00.
• On Thursday, June 18th, Andrew Guggenhime sold 10,000 shares of Vaxcyte stock. The shares were sold at an average price of $53.00, for a total value of $530,000.00.

Vaxcyte Stock Down 1.4%

Vaxcyte stock opened at $58.07 on Friday. The business has a 50 day moving average price of $53.85 and a two-hundred day moving average price of $55.21. Vaxcyte, Inc. has a 12 month low of $29.29 and a 12 month high of $65.00. The stock has a market cap of $8.39 billion, a price-to-earnings ratio of -7.61 and a beta of 1.23.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.06) by $0.09. During the same period last year, the business posted ($1.22) EPS. On average, analysts expect that Vaxcyte, Inc. will post -7.91 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Zacks Research downgraded shares of Vaxcyte from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Wall Street Zen raised shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research note on Saturday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $86.00.

Institutional Investors Weigh In On Vaxcyte

Several large investors have recently made changes to their positions in PCVX. Smartleaf Asset Management LLC lifted its holdings in Vaxcyte by 156.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after purchasing an additional 364 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its stake in Vaxcyte by 1,463.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock worth $30,000 after buying an additional 600 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Vaxcyte by 33.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after buying an additional 184 shares in the last quarter. CIBC Private Wealth Group LLC increased its holdings in shares of Vaxcyte by 22,500.0% during the third quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock worth $49,000 after buying an additional 1,350 shares in the last quarter. Finally, Capital Advisors Ltd. LLC bought a new position in shares of Vaxcyte in the first quarter valued at approximately $58,000. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.